Sonic Healthcare Limited (?Sonic?) announced that it has signed an agreement to form a Joint Venture (?JV?) company with Harrison.ai, to co-develop and commercialise effective and accurate clinical Artificial Intelligence (AI) solutions in pathology. In addition to forming the JV, Sonic Healthcare has taken a significant strategic shareholding in Harrison.ai. As one of the large providers of pathology /laboratory medicine in the world, the creation of this JV marks another positive step in Sonic's strategy to remain at the forefront of medical diagnostics. Based in Sydney, Harrison.ai is an internationally renowned company with a proven track record of building, validating and commercialising high-performance clinical AI tools at pace. With a team of more than 250 data scientists, engineers, and other staff across the group, Harrison.ai has developed clinical AI solutions in Imaging and IVF that already impact more than 50,000 patients each month and are approved for clinical use in Australia, UK, Europe and other countries. Harrison.ai and I-MED Radiology Network formed Annalise.ai in early 2020, a company that develops AI solutions for radiology. Sonic has entered into commercial arrangements with Annalise.ai to utilise its products, including Annalise CXR, which was developed and commercialised in just 18 months to become the world's most comprehensive AI clinical decision-support solution for chest X-rays. Annalise CXR was featured in peer-reviewed journal Lancet Digital Health as capable of detecting an unprecedented 124 findings in chest X-rays. Sonic is currently implementing the solution at more than 100 radiology clinics around Australia. With a shared vision to deliver high quality healthcare, the JV combines Harrison.ai's depth of expertise and comprehensive AI methodologies with Sonic Healthcare's clinical experience and distribution, to create new powerful AI applications to support clinicians to more effectively and efficiently diagnose patients in pathology.